3 Healthcare Stocks for 3 Stages of Life

Key Points

• The healthcare sector offers options for investors of every age, combining high-growth drugmakers, defensive operators, and reliable dividend payers.
• Eli Lilly suits younger investors with its obesity and diabetes drug pipeline driving growth, having gained nearly 34% since its April low.
• UnitedHealth Group fits middle-aged investors with a turnaround story and rising dividend, while Johnson & Johnson's Dividend King status appeals to older, income-focused investors.

When it comes to investing, there is no one-size-fits-all approach. Strategies vary based on numerous factors, including but not limited to investors’ risk tolerance, net worth, and age. When it comes to stock-picking, that last one is important.

Conventional wisdom says that younger investors with longer horizons should focus on decades of exposure to growth stocks. Middle-aged investors may want to reduce their risk profile while seeking out a combination of growth and yield. Older investors tend to home in on income generation.

While higher-volatility growth sectors like tech and communication services don’t necessarily fit the bill, some sectors offer something for every investor regardless of their age. The healthcare sector is one of those. And after an unremarkable start to the year, that corner of the market has been on a tear in the second half.

Healthcare’s mix of high-growth drugmakers, defensive operators, and reliable dividend payers gives investors several ways to participate in the sector’s recent strength.

For Young Investors: Eli Lilly

Eli Lilly NYSE: LLY, which was founded in 1876, may not be the first thing to come to mind when younger investors think of growth stocks.

Eli Lilly is the largest member of Big Pharma and the only one with a valuation north of $1 trillion.

But because of its dynamic portfolio of diabetes, cancer, Alzheimer’s, and obesity drugs, it acts like a growth stock.

Its lineup of obesity treatments is a particular driver of that growth. The company makes injectable Zepbound and Foundayo, a daily oral tablet for chronic weight management.

So far this year, LLY has underperformed the market. But since its year-to-date (YTD) low on April 29, shares have rallied nearly 34%. Over the past five years, the stock has gained around 390%.

Eli Lilly provides a modest dividend that yields 0.61%, or $6.92 per share annually, and has increased that payout for 11 consecutive years, with a five-year annualized growth rate of 15.18% and a healthy and sustainable payout ratio 23.22%.

While some of the GLP-1 growth is likely priced into the stocks of companies providing those drugs, there are years of increasing demand ahead for the industry. Grand View Research forecasts that the global obesity treatment market will undergo a compound annual growth rate (CAGR) of 22.3% from 2025 to 2030, while the global GLP-1 weight loss drug market will see an 18.5% CAGR during the same period.

Of the 30 analysts currently covering LLY, 25 assign it a Buy rating. Overall, the stock receives a consensus Moderate Buy rating and an average 12-month price target that suggests as much as 14% potential upside.

For Middle-Aged Investors: UnitedHealth Group

UnitedHealth Group NYSE: UNH has had a well-documented turnaround.

After shedding more than 60% from April 11, 2025, to its five-year low on Aug. 1, 2025, the stock has regained more than more than 60% since, including a market-beating 14% YTD performance so far in 2026.

The company’s Medicaid performance is improving. UnitedHealth expects margins closer to 1.1% loss rather than the previous 1.7% loss it projected, while management still expects 2026 to be the trough before moving toward breakeven or profitability in 2027

Regarding Medicare Advantage, CFO Wayne DeVeydt has said UnitedHealth’s first-half performance supported its expectation of landing in the upper half of its previously stated 2% to 4% margin range for the year.

Importantly, after its difficult 2025, the company has posted four consecutive earnings beats, and after reporting Q2 results on July 16, management raised full-year 2026 outlook to adjusted earnings per share (EPS) of $19.50 to $20 and higher operating earnings for both UnitedHealthcare and Optum Health after a stronger-than-expected quarter.

Of the 27 analysts covering UNH, 21 assign it a Buy rating. Overall, the stock receives a consensus Moderate Buy rating and an average 12-month price target that suggests more than 19% potential upside.

For middle-aged investors, its worth nothing that the that growth is combined with a steady dividend, which UnitedHealth has increased for 15 consecutive years. It yields 2.42%, or $9.28 per share annually. And while the payout ratio of nearly 60% could be a concern, UNH’s annualized five-year dividend growth rate is 12.57%.

For Older Investors: Johnson & Johnson

As far as healthcare stocks go, Johnson & Johnson NYSE: JNJ is often considered an ideal fit for an income investor’s portfolio.

Having achieved Dividend King status 14 years ago, JNJ yields 2.03%, or $5.36 per share annually.

Its payout ratio of 62.11% is somewhat elevated and its five-year annualized dividend growth rate of 5.25% isn’t as impressive as the other two stocks on this list.

But JNJ is the quintessential steady portfolio compounder. In addition to its dividend, the stock has posted a 28% YTD gain, and over the past five years, shares are up nearly 60%.

That combination of growth and reliable yield makes it a rarity in a defensive sector like healthcare, offering older investors the best of both worlds.

Of the 25 analysts currently covering JNJ, 19 assign it a Buy rating. Overall, it receives a consensus Moderate Buy rating alongside an average 12-month price target that suggests around 3.5% potential upside.